Search details
1.
Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up.
Breast Cancer Res Treat
; 197(3): 569-582, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36469156
2.
Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Breast Cancer Res Treat
; 194(2): 221-230, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35699854
3.
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
Int J Cancer
; 148(3): 692-701, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-32700765
4.
Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Acta Pharmacol Sin
; 42(8): 1368-1375, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33154554
5.
Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Lancet Oncol
; 20(11): e619-e626, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31674320
6.
Clinical development of immuno-oncology in China.
Lancet Oncol
; 21(8): 1013-1016, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32758460
7.
Availability of anticancer biosimilars in 40 countries.
Lancet Oncol
; 21(2): 197-201, 2020 02.
Article
in English
| MEDLINE | ID: mdl-32007192
8.
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 16(4): 436-46, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25795409
9.
[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Zhonghua Zhong Liu Za Zhi
; 35(3): 207-11, 2013 Mar.
Article
in Zh
| MEDLINE | ID: mdl-23880002
10.
[Association of genetic variantions of circadian clock genes and risk of breast cancer].
Zhonghua Zhong Liu Za Zhi
; 35(3): 236-9, 2013 Mar.
Article
in Zh
| MEDLINE | ID: mdl-23880009
11.
[Clinical analysis of 34 patients with adrenal metastasis from breast cancer].
Zhonghua Zhong Liu Za Zhi
; 35(11): 855-7, 2013 Nov.
Article
in Zh
| MEDLINE | ID: mdl-24447485
12.
[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Zhonghua Zhong Liu Za Zhi
; 35(7): 521-4, 2013 Jul.
Article
in Zh
| MEDLINE | ID: mdl-24257305
13.
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
J Huazhong Univ Sci Technolog Med Sci
; 33(2): 262-265, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23592141
14.
[Effects of polysomy 17 on HER-2 gene and protein expression and its clinicopathologic significance in breast cancer].
Zhonghua Yi Xue Za Zhi
; 93(2): 84-8, 2013 Jan 08.
Article
in Zh
| MEDLINE | ID: mdl-23648340
15.
Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study.
Cancer Med
; 12(5): 5323-5333, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36281495
16.
Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study.
Front Oncol
; 13: 978985, 2023.
Article
in English
| MEDLINE | ID: mdl-36761968
17.
[Endobronchial metastases from breast cancer: a clinicopathological and survival analysis].
Zhonghua Zhong Liu Za Zhi
; 34(5): 394-7, 2012 May.
Article
in Zh
| MEDLINE | ID: mdl-22883465
18.
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Zhonghua Zhong Liu Za Zhi
; 34(6): 465-8, 2012 Jun.
Article
in Zh
| MEDLINE | ID: mdl-22967451
19.
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Zhonghua Zhong Liu Za Zhi
; 34(10): 770-4, 2012 Oct.
Article
in Zh
| MEDLINE | ID: mdl-23291072
20.
[Prognostic factors and analyses of different therapeutic strategies in HR+ breast cancer patients with bone-only metastases].
Zhonghua Yi Xue Za Zhi
; 92(46): 3279-82, 2012 Dec 11.
Article
in Zh
| MEDLINE | ID: mdl-23328514